A multisystem approach for development and evaluation of inactivated vaccines for Venezuelan equine encephalitis virus (VEEV).
(73/140)
(+info )Comparison of the immunological responses and efficacy of gamma-irradiated V3526 vaccine formulations against subcutaneous and aerosol challenge with Venezuelan equine encephalitis virus subtype IAB.
(74/140)
(+info )Development of a novel monoclonal antibody with reactivity to a wide range of Venezuelan equine encephalitis virus strains.
(75/140)
(+info )T cells facilitate recovery from Venezuelan equine encephalitis virus-induced encephalomyelitis in the absence of antibody.
(76/140)
(+info )Evaluation of formalin inactivated V3526 virus with adjuvant as a next generation vaccine candidate for Venezuelan equine encephalitis virus.
(77/140)
(+info )Venezuelan equine encephalitis and 2 human deaths, Peru.
(78/140)
(+info )The first human epitope map of the alphaviral E1 and E2 proteins reveals a new E2 epitope with significant virus neutralizing activity.
(79/140)
(+info )Interplay of acute and persistent infections caused by Venezuelan equine encephalitis virus encoding mutated capsid protein.
(80/140)
(+info )